The burgeoning landscape of therapy for excess body fat and type 2 glucose intolerance is currently witnessing considerable interest surrounding both retatrutide and tirzepatide. While both represent novel dual GIP and GLP-1 receptor agonists, significant differences in their pharmacological profiles and clinical trial results are emerging. Retatru… Read More

Emerging in the arena of obesity therapy, retatrutide represents a distinct approach. Different from many available medications, retatrutide operates as a double agonist, concurrently targeting both glucagon-like peptide-1 (GLP-1) and glucose-sensitive insulinotropic polypeptide (GIP) receptors. The dual engagement encourages multiple helpful effec… Read More